Please assess the completion status of the following clinical trial:

Trial Title: Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Poor glycemic control (HbA1c ≥7.5%)~* Stable basal bolus insulin regimen for almost a year, eventually associated with metformin.~Exclusion Criteria:~* Type 1 diabetes or secondary diabetes;~* Previous treatment for the last three months with GLP-1RA or DPP-4 inhibitors;~* Hypersensitivity towards active substances or other ingredients of the drugs used in the study~* Participation in other trial with experimental drugs within 30 days~* Diseases that represent contraindication to GLP-1RA use (pancreatitis, gallstones)~* Pregnancy or planned pregnancy within the time of the study~* Serum creatinine \> 1,3 mg/dL in women and \>1,4 mg/dL in men~* eGFR \< 30 mL/min~* Previous cancer or antineoplastic therapy for five years before randomization~* Current therapy with glucocorticoid (oral, topic or sistemic administration) or with antypsichotic drugs~* Previous ketoacidosis~* Any clinical, psychologic or psychiatric condition that is incompatible with the study according to the investigator

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- FR insulin/GLP-1RA (Type: ACTIVE_COMPARATOR): Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
- Insulin/SGLT-2i (Type: ACTIVE_COMPARATOR): Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
- Basal Bolus (Type: ACTIVE_COMPARATOR): Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals

Based on this trial design, predict the completion outcome and termination type (if applicable).